The authors aim to provide essential information on various clinical cases on urological cancers. The main messages are well referenced and the texts phrasing is written in a simple and user-friendly style. The book also contains summarizing tables and high quality original pictures. Several expert panels (American Urologists Association, European Association of Urologists, Association Française des Urologues, etc) are proposing guidelines aiming at providing detailed recommendations to the Urologists facing difficult urological scenarios and no significant discordance exist between them since they are all based on the existing published studies dealing with different aspects of the urological cancers.

Immer mehr Urologen und Onkologen entscheiden sich beim Management urologischer Krebserkrankungen für den Erhalt und nicht die Entfernung des betroffenen Gewebes. Dieses Fachbuch erläutert alle verfügbaren Optionen und zeigt das bestmögliche Patientenmanagement. Herausgeber Mark Schoenberg ist ein international anerkannter Experte auf diesem neuen, aufregenden Gebiet und hat ein herausragendes Team zusammengestellt, zu dem einige der führenden Urologen und Onkologen aus Nordamerika und Europa gehören.

This text provides a comprehensive review of pathophysiology, molecular and cell biology aspects of CRPC, discusses all major clinical trials that have led to approval of 6 new drugs since 2004, explores the role of bone preservation strategies, in depth analysis of combination and sequencing strategies, outlines upcoming novel drugs and trends in research, and stresses the role of palliative care in this incurable disease. Managing Metastatic Prostate Cancer in Your Urological Oncology Practice will serve as a very useful resource for physicians and researchers dealing with, and interested in prostate cancer. It provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts. All chapters are written by experts in their fields and will include the most up to date scientific and clinical information.

This book provides a practical, comprehensive, state-of-the-art review of bladder cancer. A valuable resource for anyone with an interest in urothelial tumors, this text brings together a multidisciplinary team of experts who have distilled their vast years of experience and knowledge into a concise, easy to digest format. Topics covered range from importance of a pattern recognition in diagnosis and pathologic evaluation to ‘how I do it’ tips on patient selection for appropriate therapies such as chemotherapy, immunotherapy, surgery and radiation. Bridging the gap between a traditional textbook and hands-on experience, this book provides a practical guide to managing day-to-day issues and challenges and brings an algorithmic approach to avoid common pitfalls. Bladder Cancer: A Practical Guide provides a concise yet comprehensive summary of the current status of the field of bladder cancer treatment, guiding patient management and stimulating investigative efforts.

Although much progress has been made in the four years since the first edition of Management of Prostate Cancer, prostate cancer remains a significant biological, me- cal, and personal challenge for millions of men. In this interval, some important trends and observations have emerged that represent real progress in the field and which will shape the direction of clinical practice and research in the next 5–10 years. These obs- vations include: (1) a decline in prostate-related cancer mortality in the United States, likely owing to a combination of factors including screening, more aggressive and earlier therapy, and improvements in specific therapies; (2) a significant downward pathological stage migration, so that an individual’s chance of cure for a given stage, grade, and PSA is better now than it was early in the PSA era, even without associated improvements in individual therapies; (3) the recognition of new PSA isoforms that may refine screening strategies; (4) several randomized, phase III clinical trials demonstrating survival adv- tages of one form of therapy over another in selected populations (external beam rad- therapy with adjuvant hormones vs radiotherapy alone, radical prostatectomy vs observation); (5) a focus on the biology of bone and bone metastasis, and new agents that reduce skeletal-related events and which may inhibit the growth of new metastases; (6) second-generation anti-PSMA antibodies with improved potential for imaging and therapy; (7) the development and widespread adoption of nomograms that assist in cli- cal decision-making for individual patients; (8) the identification of new genes that

Urologists and medical oncologists have witnessed a rapid growth in systemic therapeutic options for treating genitourinary malignancies that increasingly integrates radiation therapy to primary cancers, nodal beds, and even metastatic sites. The culmination of these advances has been the creation of multidisciplinary teams that expertly provide comprehensive care to patients with urologic cancers. This book provides the framework to create such a multidisciplinary clinical team focused on the treatment of urologic malignancies with representation from urologists, medical oncologists, and additional specialists who work together to provide optimal team-based care. The book integrates advanced systemic therapeutics including immune-based and targeted therapies. Readers gain a better understanding of the benefit of multidisciplinary co-management through specific examples such as hormone sensitive metastatic prostate cancer, neoadjuvant chemotherapy for muscle invasive bladder cancer, and immunotherapy approaches to advanced bladder and kidney cancer. The book also discusses the integration of genomic tumor characterization and personalized medicine into surgical planning, tumor biopsies, and chemo-immunotherapy selection, emphasizing the expansion of new therapeutics for urologic malignancies and the changing definitions of disease progression. Urologic Oncology: Multidisciplinary Care for Patients is a comprehensive resource for urologists, medical oncologists, radiation oncologists, genetic counselors, fellows in urologic oncology and medical oncology, residents in urology and radiation oncology, advanced practice providers, practice managers, and pharmaceutical representatives.

This book is designed to familiarize clinical practitioners in systemic therapy options and medical management of urologic malignancies including prostate cancer, bladder and upper tract urothelial carcinoma, and renal cell carcinoma. Organized by organ system, the text highlights new therapies such as novel forms of androgen deprivation, cytotoxic chemotherapy, immune check point and immunomodulatory agents, and targeted therapies. Written by experts in the field, the book also reviews current chemotherapy and immunotherapy regimens for genitourinary malignancies and discusses indications, outcomes, and toxicities, as well as clinical trial concepts. Each of the book’s chapters offers a bulleted box of clinical pearls on the particular role of the APP. Chemotherapy and Immunotherapy in Urologic Oncology: A Guide for the Advanced Practice Provider is a resource for urologists, uro-radiologists, medical clinicians and family practitioners alike, familiarizing its audiences with systemic therapy regimens for urologic malignancies, as well as their expected outcomes and side effects.